Daicel Corporation (TYO:4202)

Market Cap	335.21B +6.8%
Revenue (ttm)	579.63B -1.2%
Net Income	10.18B -79.4%
EPS	38.74 -78.6%
Shares Out	255.40M
PE Ratio	33.88
Forward PE	7.84
Dividend	60.00 (4.57%)
Ex-Dividend Date	Mar 30, 2026

Volume	1,790,300
Average Volume	1,808,810
Open	1,332.50
Previous Close	1,312.50
Day's Range	1,330.00 - 1,374.00
52-Week Range	1,112.50 - 1,658.00
Beta	0.53
RSI	61.40
Earnings Date	May 12, 2026

About Daicel

Daicel Corporation engages in the materials, medical/healthcare, smart, safety, and engineering plastics businesses in Japan and internationally. The company offers medical/healthcare products, including BELLOCEA S7, a spherical cellulose acetate particle; FLAVOCELL S-Equol; Urolithin A; polyglycerols; konjac ceramide; excipients for foods; chiral columns and reagents; and Actranza lab, as well as separation and analytical services. It also provides performance films, solvents for electronic materials, cycloaliphatic epoxies, polymers for photo...

• Industry: Specialty Chemicals
• Sector: Materials
• Founded: 1919
• Employees: 11,178
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4202

Financial Performance

In fiscal year 2026, Daicel's revenue was 579.63 billion, a decrease of -1.18% compared to the previous year's 586.53 billion. Earnings were 10.18 billion, a decrease of -79.43%.